Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05257486 · ClinicalTrials.gov registry record
Post-market Multi-Center RETRO-Prospective Study to Assess Long-term Clinical Outcomes NMSC Patients Treated With eBx
A clinical trial, sponsored by Xoft.
- Completed
- Registry status
- 183
- Enrollment target
NCT05257486: Completed study, sponsored by Xoft.
NCT05257486 is a clinical trial that has completed, run by Xoft. The registered enrollment target is 183 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05257486 has completed, sponsored by Xoft.
- COMPLETED
- Registry status
- 183 participants
- Enrollment target
Study Summary
The purpose of this retrospective-prospective study is to evaluate lesions after treatment for BCC or SCC NMSC in order to gain a better understanding of the durability of the treatment, and risk of late toxicities for this patient population.
Primary Outcome
Physician office visit for long-term assessment to determine if recurrence of skin cancer has occurred at previously treated site for subjects who were previously treated at least 5 years prior; Subjects treated with Xoft eBx or MMS over 5 years prior were called in for a long-term prospective visit, reconsented, and assessed for skin cancer recurrence at the previously treated site.
Interventions
- DEVICE Xoft eBx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 183 participants |
| Start Date | 2022-03-09 |
| Est. Completion | 2022-10-13 |
What the finished NCT05257486 record still lists
NCT05257486 is an observational study that tracks outcomes without assigning an intervention. The registered 183 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Xoft eBx is the first listed.
NCT05257486 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05257486 about?
NCT05257486 is a clinical study titled "Post-market Multi-Center RETRO-Prospective Study to Assess Long-term Clinical Outcomes NMSC Patients Treated With eBx". The purpose of this retrospective-prospective study is to evaluate lesions after treatment for BCC or SCC NMSC in order to gain a better understanding of the durability of the treatment, and risk of late toxicities for this patient population.
What is the current status of trial NCT05257486?
This trial is currently completed. The enrollment target is 183 participants. The study started on 2022-03-09. Estimated completion is 2022-10-13.
What interventions are being tested in trial NCT05257486?
The interventions under investigation include: Xoft eBx (DEVICE).
Who is sponsoring clinical trial NCT05257486?
This trial is sponsored by Xoft, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03859297 · 183 participants · NA
Mechanisms of Rumination Change in Adolescent Depression
- NCT04270591 · 183 participants · Phase 1
Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer
- NCT06764615 · 183 participants · Phase 2
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
- NCT06872684 · 183 participants · NA
Safety and Efficacy of Endovascular Treatment of Intracranial Aneurysms With Surpass Elite With GUARDian Flow Diverter (GUARD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI